| dbo:abstract |
Crizanlizumab, sold under the brand name Adakveo & Ryverna both by Novartis, is a monoclonal antibody medication that binds to P-selectin. It is a drug used to reduce the frequency of vaso-occlusive crisis in people aged 16 years and older who have sickle cell anemia. Vaso-occlusive crisis is a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells (red cells are usually round and flexible, but sometimes many red cells in a person with sickle cell anemia will become rigid and crescent-shaped due to polymerization of hemoglobin). The result of the Phase II SUSTAIN clinical trial was published in December 2016, and in November 2019, crizanlizumab-tmca was approved in the United States. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. (en) Кризанлизумаб — моноклональное антитело для лечения серповидноклеточной анемии. Одобрен для применения: США (ноябрь 2019). (ru) |
| dbo:alternativeName |
Adakveo (en) |
| dbo:casNumber |
1690318-25-2 |
| dbo:drugbank |
DB15271 |
| dbo:fdaUniiCode |
L7451S9126 |
| dbo:kegg |
D11480 |
| dbo:medlinePlus |
a620010 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/name/crizanlizumab |
| dbo:wikiPageID |
52481577 (xsd:integer) |
| dbo:wikiPageLength |
8998 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1090917138 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Priority_review dbr:Intravenous_therapy dbr:Orphan_drug dbr:Endothelial_cell dbr:Monoclonal_antibody dbc:Sickle-cell_disease dbr:Polymerization dbc:Orphan_drugs dbr:Food_and_Drug_Administration dbr:Breakthrough_therapy dbr:Novartis dbc:Hematology dbc:Breakthrough_therapy dbc:Monoclonal_antibodies dbr:First-in-class_medication dbr:P-selectin dbr:Vaso-occlusive_crisis dbr:Sickle_cell_anemia dbr:Selectin_P |
| dbp:atcPrefix |
B06 (en) |
| dbp:atcSuffix |
AX01 (en) |
| dbp:c |
6458 (xsd:integer) |
| dbp:casNumber |
1690318 (xsd:integer) |
| dbp:chemspiderid |
none (en) |
| dbp:dailymedid |
Crizanlizumab (en) |
| dbp:drugbank |
DB15271 (en) |
| dbp:h |
9948 (xsd:integer) |
| dbp:kegg |
D11480 (en) |
| dbp:legalAu |
S4 (en) |
| dbp:legalEu |
Rx-only (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:licenceUs |
Adakveo (en) |
| dbp:mabType |
mab (en) |
| dbp:medlineplus |
a620010 (en) |
| dbp:n |
1712 (xsd:integer) |
| dbp:o |
2050 (xsd:integer) |
| dbp:pregnancyAu |
B1 (en) |
| dbp:routesOfAdministration |
dbr:Intravenous_therapy |
| dbp:s |
58 (xsd:integer) |
| dbp:source |
zu (en) |
| dbp:synonyms |
SEG101, SelG1, crizanlizumab-tmca (en) |
| dbp:target |
dbr:Selectin_P |
| dbp:tradename |
Adakveo (en) |
| dbp:type |
mab (en) |
| dbp:unii |
L7451S9126 (en) |
| dbp:wikiPageUsesTemplate |
dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Use_dmy_dates dbt:Drugs.com dbt:Blood-drug-stub dbt:Monoclonals_for_immune_system |
| dct:subject |
dbc:Sickle-cell_disease dbc:Orphan_drugs dbc:Hematology dbc:Breakthrough_therapy dbc:Monoclonal_antibodies |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody dbo:Drug |
| rdfs:comment |
Кризанлизумаб — моноклональное антитело для лечения серповидноклеточной анемии. Одобрен для применения: США (ноябрь 2019). (ru) Crizanlizumab, sold under the brand name Adakveo & Ryverna both by Novartis, is a monoclonal antibody medication that binds to P-selectin. It is a drug used to reduce the frequency of vaso-occlusive crisis in people aged 16 years and older who have sickle cell anemia. Vaso-occlusive crisis is a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells (red cells are usually round and flexible, but sometimes many red cells in a person with sickle cell anemia will become rigid and crescent-shaped due to polymerization of hemoglobin). (en) |
| rdfs:label |
Crizanlizumab (en) Кризанлизумаб (ru) |
| owl:sameAs |
wikidata:Crizanlizumab dbpedia-fa:Crizanlizumab dbpedia-ru:Crizanlizumab https://global.dbpedia.org/id/2d7N4 yago-res:Crizanlizumab |
| prov:wasDerivedFrom |
wikipedia-en:Crizanlizumab?oldid=1090917138&ns=0 |
| foaf:isPrimaryTopicOf |
wikipedia-en:Crizanlizumab |
| is dbo:wikiPageRedirects of |
dbr:Adakveo |
| is dbo:wikiPageWikiLink of |
dbr:List_of_drugs_granted_breakthrough_therapy_designation dbr:Antiserum dbr:Glioblastoma dbr:Sickle_cell_disease dbr:Adakveo dbr:ATC_code_B06 dbr:List_of_therapeutic_monoclonal_antibodies dbr:P-selectin |
| is foaf:primaryTopic of |
wikipedia-en:Crizanlizumab |